Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
Company provides 2026 corporate outlook highlighting multiple clinical catalysts across first-in-class cardioendocrine pipeline MAR002 Phase 1 Data: Robust, durable IGF-1 suppression supports potential for biweekly to monthly dosing; Phase 2/3 study initiation expected mid-2026 MAR001 Phase 2b TYDAL-TIMI 78 Study Enrollment Nearing Completion: multiple data readouts expected throughout 2026; advancing half-life-extended MAR001-HLE designed for infrequent, low-volume subcutaneous dosing toward Phase 3 readiness Pipeline Expansion: Advancing next-generation siRNA portfolio with development candidate nomination(s) expected in 2026 Management to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, at 10:30 a.m. […]